Noxafil — CareFirst (Caremark)

Preferred products

• fluconazole
• itraconazole oral solution

Initial criteria

• For oropharyngeal candidiasis: the request is for Noxafil oral suspension (immediate-release)
• For oropharyngeal candidiasis: patient has experienced an inadequate treatment response, intolerance, or has a contraindication to fluconazole AND itraconazole oral solution
• For prevention of invasive Aspergillus and Candida infections: requested drug is being prescribed for a patient who is at high risk of developing these infections due to being severely immunocompromised
• For treatment of invasive aspergillosis: requested drug is for Noxafil injection or Noxafil delayed-release tablets

Approval duration

Oropharyngeal candidiasis: 1 month; Prevention of invasive Aspergillus and Candida infections: 6 months; Treatment of invasive aspergillosis: 3 months